StockData
Inhibikase Therapeutics, Inc. logo

Inhibikase Therapeutics, Inc. (IKT) stock

IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$1.38−0.07 (-4.83%)

Close on Nov 17, 2026Market cap $192.56MP/E –Yield –

Inhibikase Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Inhibikase Therapeutics's operating margin for the twelve months ending Sep 30, 2024 was -2006393700.0%. For fiscal 2023 it was -7712.0%, against -14686.2% the year before.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2023Dec 31, 2023-7712.0%+6974.2
FY2022Dec 31, 2022-14686.2%−14209.9
FY2021Dec 31, 2021-476.2%−72.7
FY2020Dec 31, 2020-403.5%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2023Dec 31, 2023-440356600.0%−440349780.4
Q3 FY2023Sep 30, 2023-5993.4%+55906.2
Q2 FY2023Jun 30, 2023-5328.1%+65489.1
Q1 FY2023Mar 31, 2023-7307.6%+2773.8
Q4 FY2022Dec 31, 2022-6819.6%−6626.8
Q3 FY2022Sep 30, 2022-61899.6%−61713.0
Q2 FY2022Jun 30, 2022-70817.1%−70112.5
Q1 FY2022Mar 31, 2022-10081.5%−8320.0
Q2 FY2021Jun 30, 2021-192.8%−4.3
Q1 FY2021Mar 31, 2021-186.6%+12.9
Q4 FY2020Dec 31, 2020-704.7%–
Q3 FY2020Sep 30, 2020-1761.4%–
Q2 FY2020Jun 30, 2020-188.5%–
Q1 FY2020Mar 31, 2020-199.4%–

More Inhibikase Therapeutics figures

See a number that looks wrong?